Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a Sector ...

Scotiabank analyst Louise Chen initiated coverage of Sarepta (SRPT) with a Sector Perform rating and $105 price target The firm says that ...

Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, ...

EST Sarepta (SRPT) files automatic mixed securities shelfDiscover the Best Stocks and Maximize Your Portfolio: See what stocks are ...

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price target reduced by Royal Bank of Canada from $165.00 to $161.00 ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by stock analysts at HC ...

Q4 2024 Earnings Call Transcript February 26, 2025 Sarepta Therapeutics, Inc. beats earnings expectations. Reported EPS is $1 ...

Good afternoon, and welcome to the Sarepta Therapeutics fourth quarter and full year 2024 financial results conference call.

CAMBRIDGE, Mass. - Sarepta Therapeutics (NASDAQ: SRPT) reported fourth quarter earnings that beat analyst expectations, but the stock fell 4.6% as investors focused on rising expenses.